Faisal Khurshid, an analyst from Leerink Partners, reiterated the Buy rating on Zura Bio (ZURA – Research Report). The associated price target is $12.00.
Faisal Khurshid has given his Buy rating due to a combination of factors that highlight Zura Bio’s potential for growth and positive developments. The company is advancing two Phase 2 studies for its lead asset, tibulizumab, targeting systemic sclerosis and hidradenitis suppurativa, with data expected in the second half of 2026. Despite a perceived lack of immediate catalysts, Khurshid emphasizes the importance of several external data catalysts that could significantly impact Zura Bio’s stock perception in the near term.
One of the most critical external catalysts is the upcoming Phase 2 data for Novartis’s anti-BAFF-R program, ianalumab, expected in the first half of 2025. If these data are positive, they would validate the BAFF targeting approach in hidradenitis suppurativa, which is a key component of tibulizumab’s mechanism. This validation, combined with the already established efficacy of IL-17 therapies, could strengthen the mechanistic rationale for tibulizumab and enhance its competitive position in the market.
Khurshid covers the Healthcare sector, focusing on stocks such as Geron, Pliant Therapeutics, and Zura Bio. According to TipRanks, Khurshid has an average return of 31.2% and a 43.86% success rate on recommended stocks.
Questions or Comments about the article? Write to editor@tipranks.com